Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin J Bergman

Showing results (21-30 of 40) with videos related to

Pageof 4
Sort By:
Rheumatology and Therapy|October 18, 2016
Response to Biologic Disease-Modifying Anti-Rheumatic Drugs after Discontinuation of Anti-Tumor Necrosis Factor Alpha Agents for Rheumatoid ArthritisMartin J Bergman, Eric P Elkin, Sarika Ogale, et al.
Arthritis Care & Research|April 13, 2011
RAPID3 (Routine Assessment of Patient Index Data 3) severity categories and response criteria: Similar results to DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) in the RAPID 1 (Rheumatoid Arthritis Prevention of Structural Damage) clinical trial of certolizumab pegolTheodore Pincus, Victoria Furer, Edward Keystone, et al.
Plos One|September 18, 2015
The Prevalence and Characteristics of Fibromyalgia in the 2012 National Health Interview SurveyBrian Walitt, Richard L Nahin, Robert S Katz, et al.
The Journal of Rheumatology|August 3, 2015
Patient Expectations and Perceptions of Goal-setting Strategies for Disease Management in Rheumatoid ArthritisVibeke Strand, Grace C Wright, Martin J Bergman, et al.
The Journal of Rheumatology|November 18, 2011
Proposed severity and response criteria for Routine Assessment of Patient Index Data (RAPID3): results for categories of disease activity and response criteria in abatacept clinical trialsTheodore Pincus, Patricia Hines, Martin J Bergman, et al.
Arthritis Care & Research|August 27, 2016
Routine Assessment of Patient Index Data 3 and the American College of Rheumatology/European League Against Rheumatism Provisional Remission Definitions as Predictors of Radiographic Outcome in a Rheumatoid Arthritis Clinical Trial With TocilizumabMuznay N Khawaja, Martin J Bergman, Jeffrey Yourish, et al.
RMD Open|December 12, 2017
MDHAQ/RAPID3 scores in patients with osteoarthritis are similar to or higher than in patients with rheumatoid arthritis: a cross-sectional study from current routine rheumatology care at four sitesCarlos El-Haddad, Isabel Castrejon, Kathryn A Gibson, et al.
Clinical and Experimental Rheumatology|October 18, 2019
Osteoarthritis is as severe as rheumatoid arthritis: evidence over 40 years according to the same measure in each diseaseTheodore Pincus, Isabelle Castrejon, Yusuf Yazici, et al.
The Journal of Rheumatology|October 17, 2018
Minimal Clinically Important Improvement of Routine Assessment of Patient Index Data 3 in Rheumatoid ArthritisMichael M Ward, Isabel Castrejon, Martin J Bergman, et al.
Rheumatology and Therapy|August 16, 2020
Clinical Utility and Cost Savings in Predicting Inadequate Response to Anti-TNF Therapies in Rheumatoid ArthritisMartin J Bergman, Alan J Kivitz, Dimitrios A Pappas, et al.
Pageof 4

Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
Rheumatology and Therapy|October 18, 2016
Response to Biologic Disease-Modifying Anti-Rheumatic Drugs after Discontinuation of Anti-Tumor Necrosis Factor Alpha Agents for Rheumatoid ArthritisMartin J Bergman, Eric P Elkin, Sarika Ogale, et al.
Arthritis Care & Research|April 13, 2011
RAPID3 (Routine Assessment of Patient Index Data 3) severity categories and response criteria: Similar results to DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) in the RAPID 1 (Rheumatoid Arthritis Prevention of Structural Damage) clinical trial of certolizumab pegolTheodore Pincus, Victoria Furer, Edward Keystone, et al.
Plos One|September 18, 2015
The Prevalence and Characteristics of Fibromyalgia in the 2012 National Health Interview SurveyBrian Walitt, Richard L Nahin, Robert S Katz, et al.
The Journal of Rheumatology|August 3, 2015
Patient Expectations and Perceptions of Goal-setting Strategies for Disease Management in Rheumatoid ArthritisVibeke Strand, Grace C Wright, Martin J Bergman, et al.
The Journal of Rheumatology|November 18, 2011
Proposed severity and response criteria for Routine Assessment of Patient Index Data (RAPID3): results for categories of disease activity and response criteria in abatacept clinical trialsTheodore Pincus, Patricia Hines, Martin J Bergman, et al.
Arthritis Care & Research|August 27, 2016
Routine Assessment of Patient Index Data 3 and the American College of Rheumatology/European League Against Rheumatism Provisional Remission Definitions as Predictors of Radiographic Outcome in a Rheumatoid Arthritis Clinical Trial With TocilizumabMuznay N Khawaja, Martin J Bergman, Jeffrey Yourish, et al.
RMD Open|December 12, 2017
MDHAQ/RAPID3 scores in patients with osteoarthritis are similar to or higher than in patients with rheumatoid arthritis: a cross-sectional study from current routine rheumatology care at four sitesCarlos El-Haddad, Isabel Castrejon, Kathryn A Gibson, et al.
Clinical and Experimental Rheumatology|October 18, 2019
Osteoarthritis is as severe as rheumatoid arthritis: evidence over 40 years according to the same measure in each diseaseTheodore Pincus, Isabelle Castrejon, Yusuf Yazici, et al.
The Journal of Rheumatology|October 17, 2018
Minimal Clinically Important Improvement of Routine Assessment of Patient Index Data 3 in Rheumatoid ArthritisMichael M Ward, Isabel Castrejon, Martin J Bergman, et al.
Rheumatology and Therapy|August 16, 2020
Clinical Utility and Cost Savings in Predicting Inadequate Response to Anti-TNF Therapies in Rheumatoid ArthritisMartin J Bergman, Alan J Kivitz, Dimitrios A Pappas, et al.
Pageof 4